Correspondence 0001493152-24-034834 from MANGOCEUTICALS, INC. (MGRX)
MANGOCEUTICALS, INC.
Date: Sept. 3, 2024 · CIK: 0001938046 · Accession: 0001493152-24-034834
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-281617
Letter
MANGOCEUTICALS, INC.
N. Dallas Parkway, Suite 600
Dallas, Texas 75248
September 3, 2024
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
F Street, N.E.
Washington, D.C. 20549
Attention: Abby Adams
Re: Mangoceuticals, Inc.
Registration Statement on Form S-1
Filed August 16, 2024
File No. 333-281617
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Mangoceuticals, Inc., hereby requests acceleration of effectiveness of the above referenced Registration Statement on Form S-1 so that it will become effective at 4:30 p.m., Eastern Daylight Time, on Thursday, September 5, 2024, or as soon thereafter as practicable.
Very
truly yours,
/s/
Jacob D. Cohen
Show Raw Text
CORRESP
1
filename1.htm
MANGOCEUTICALS,
INC.
15110
N. Dallas Parkway, Suite 600
Dallas,
Texas 75248
September
3, 2024
VIA
EDGAR
U.S.
Securities and Exchange Commission
Division
of Corporation Finance
100
F Street, N.E.
Washington,
D.C. 20549
Attention:
Abby Adams
Re:
Mangoceuticals,
Inc.
Registration
Statement on Form S-1
Filed
August 16, 2024
File
No. 333-281617
Ladies
and Gentlemen:
Pursuant
to Rule 461 under the Securities Act of 1933, as amended, Mangoceuticals, Inc., hereby requests acceleration of effectiveness of the
above referenced Registration Statement on Form S-1 so that it will become effective at 4:30 p.m., Eastern Daylight Time, on Thursday,
September 5, 2024, or as soon thereafter as practicable.
Very
truly yours,
/s/
Jacob D. Cohen
Jacob
D. Cohen
Chairman
and Chief Executive Officer
cc:
Lucosky
Brookman LLP